To fund its Consumer Healthcare Business
Strides Pharma Science announced that its board of directors have approved the execution by Strides of definitive agreements with funds advised by ICP‐III Investment Advisors (ICP) to provide growth capital and focused attention to its Consumer Healthcare Business (CHC). ICP would provide the business with a USD 20 Million capital for growth. The CHC business comprises of key brands including JointFlex, Pediacare, NiteThru and NixIt sold across key regulated and emerging markets. The business had Revenues of USD 6.4 Million for FY18.The proposed transaction will be subject to customary closing conditions.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
